This Article Full Text Full Text (PDF) All Versions of this Article: 91/1/79    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strock, C. J. Articles by Nelkin, B. D. Search for Related Content PubMed PubMed Citation Articles by Strock, C. J. Articles by Nelkin, B. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Chemotherapy Thyroid Cancer Related Collections Endocrine Oncology Thyroid

Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (C.J.S., J.-I.P., D.M.R., S.R.D., D.W.B., B.D.N.) and Department of Medicine, Johns Hopkins University School of Medicine (D.W.B.), Baltimore, Maryland 21231; and Cephalon, Inc. (B.R.), West Chester, Pennsylvania 19380

Address all correspondence and requests for reprints to: Dr. Barry Nelkin, CRB, Room 552, 1650 Orleans Street, Baltimore, Maryland 21231. E-mail: bnelkin{at}jhmi.edu.

Context: Medullary thyroid cancer (MTC) is a cancer of the parafollicular C cells that commonly presents with an inherited or acquired RET gene mutation. There is currently no effective systemic treatment for MTC.

Objective: The objective of this study was to investigate a systemic therapeutic approach to treat MTC. We studied the sensitivity of an MTC cell line and xenograft to irinotecan, alone and in combination with the tyrosine kinase inhibitor, CEP-751.

Results: In TT cell culture and xenografts, irinotecan treatment was highly effective. This effect was augmented by treatment with CEP-751. Treatment of TT cell xenografts resulted in durable complete remission in 100% of the mice, with median time to recurrence of 70 d for irinotecan alone and more than 130 d for irinotecan plus CEP-751. Although irinotecan induced an S phase checkpoint arrest in TT cells, CEP-751 in combination with irinotecan resulted in a loss of this arrest. CEP-751 induced a loss in the induction of the DNA repair program marked by phospho-H2AX and the checkpoint pathway marked by the activated Chk1 pathway.

Conclusions: Irinotecan treatment was highly effective in a preclinical model of human MTC, resulting in complete remission in 100% of the xenografts treated. The duration of remission was further enhanced by combination with the kinase inhibitor, CEP-751. These results suggest that irinotecan, alone or in combination, may be useful for the treatment of MTC.

This article has been cited by other articles:

				A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585. [Abstract] [Full Text] [PDF]

				K. Frank-Raue, M. Fabel, S. Delorme, U. Haberkorn, and F. Raue Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma Eur. J. Endocrinol., August 1, 2007; 157(2): 215 - 220. [Abstract] [Full Text] [PDF]

				K. A. B. Knostman, S. M. Jhiang, and C. C. Capen Genetic Alterations in Thyroid Cancer: The Role of Mouse Models Vet. Pathol., January 1, 2007; 44(1): 1 - 14. [Abstract] [Full Text] [PDF]

				H. AHLMAN Malignant pheochromocytoma: state of the field with future projections. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 449 - 464. [Abstract] [Full Text] [PDF]